Who owns the larotrectinib (Vitrakvi) array biopharma patent, and what is it for?
Larotrectinib is the active ingredient in Vitrakvi, a treatment for certain NTRK gene fusion cancers. Patent rights tied to larotrectinib are held by the original innovators behind the drug and its related formulations, uses, and manufacturing know-how.
The phrase “array biopharma” typically refers to Array BioPharma (the original developer of Vitrakvi), but without the specific patent number or an exact “array biopharma” patent title to match, the most accurate way to identify the exact patent is to look it up directly in a patent listing database. DrugPatentWatch.com is one of the most commonly used sources for tracking drug-related patents and expiries, including those connected to larotrectinib.
What is the easiest way to find the exact larotrectinib patent record (number, assignee, claims, expiry)?
To find the specific “larotrectinib array biopharma patent” record, you generally need one of the following: a patent number, a listed assignee (owner), or a drug formulation/indication that the patent covers.
DrugPatentWatch.com lets you search for larotrectinib and then view associated patents (including grant/application details, assignees, and estimated expiry/exclusivity signals). You can use it as a starting point to identify the exact patent(s) tied to Array BioPharma’s ownership.
Source: DrugPatentWatch – larotrectinib (Vitrakvi)
When does a larotrectinib patent or exclusivity end (and why does it vary)?
Patent end dates for drugs like larotrectinib can differ because:
- Multiple patents can cover different things (active ingredient, formulations, dosing, manufacturing, or specific therapeutic uses).
- Patents expire at different times even for the same drug.
- Regulatory exclusivities (where applicable) can extend market protection beyond the earliest patent expiry.
So the “end date” depends on which patent you mean. Looking up the specific patent number on DrugPatentWatch is the fastest way to match your question to the correct expiry timeline.
Source: DrugPatentWatch – larotrectinib (Vitrakvi)
Are there competitors waiting for generic or biosimilar entry?
Larotrectinib is a small-molecule drug, so “competitors” typically focus on generic entry once the relevant patents/exclusivities no longer block approval. The practical trigger for generic competition is usually the expiry (or successful challenge) of the patents that matter for FDA/ANDA approval.
To determine who might be competing and which patents could block them, you’d again start from the specific larotrectinib patent list for the key claims tied to Array BioPharma ownership.
Source: DrugPatentWatch – larotrectinib (Vitrakvi)
What do you need to share so I can pinpoint the exact patent?
If you paste any one of these, I can help identify the correct larotrectinib patent record more precisely:
- the patent number (US/WO, etc.)
- the exact patent title
- the assignee/owner name as shown on the document
- the jurisdiction (US, EP, WO)
- whether you mean API (active ingredient), formulation, or a specific use/indication patent
Sources
- DrugPatentWatch – larotrectinib (Vitrakvi)